Literature DB >> 27473041

First-Line Chemotherapy for Ovarian Cancer: Inferences From Recent Studies.

Peter G Rose1.   

Abstract

Entities:  

Year:  2016        PMID: 27473041      PMCID: PMC5189620          DOI: 10.1634/theoncologist.2016-0144

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


× No keyword cloud information.
  24 in total

1.  Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

Authors:  Deborah K Armstrong; Brian Bundy; Lari Wenzel; Helen Q Huang; Rebecca Baergen; Shashikant Lele; Larry J Copeland; Joan L Walker; Robert A Burger
Journal:  N Engl J Med       Date:  2006-01-05       Impact factor: 91.245

2.  A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.

Authors:  M Friedlander; M J Millward; D Bell; R Bugat; P Harnett; J A Moreno; L Campbell; C Varette; V Ripoche; L Kayitalire
Journal:  Ann Oncol       Date:  1998-12       Impact factor: 32.976

3.  A phase 3 trial of bevacizumab in ovarian cancer.

Authors:  Timothy J Perren; Ann Marie Swart; Jacobus Pfisterer; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Christian Kurzeder; Andreas du Bois; Jalid Sehouli; Rainer Kimmig; Anne Stähle; Fiona Collinson; Sharadah Essapen; Charlie Gourley; Alain Lortholary; Frédéric Selle; Mansoor R Mirza; Arto Leminen; Marie Plante; Dan Stark; Wendi Qian; Mahesh K B Parmar; Amit M Oza
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

4.  Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

Authors:  D S Alberts; P Y Liu; E V Hannigan; R O'Toole; S D Williams; J A Young; E W Franklin; D L Clarke-Pearson; V K Malviya; B DuBeshter
Journal:  N Engl J Med       Date:  1996-12-26       Impact factor: 91.245

5.  Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

Authors:  M J Piccart; K Bertelsen; K James; J Cassidy; C Mangioni; E Simonsen; G Stuart; S Kaye; I Vergote; R Blom; R Grimshaw; R J Atkinson; K D Swenerton; C Trope; M Nardi; J Kaern; S Tumolo; P Timmers; J A Roy; F Lhoas; B Lindvall; M Bacon; A Birt; J E Andersen; B Zee; J Paul; B Baron; S Pecorelli
Journal:  J Natl Cancer Inst       Date:  2000-05-03       Impact factor: 13.506

6.  Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.

Authors:  A N Gordon; J T Fleagle; D Guthrie; D E Parkin; M E Gore; A J Lacave
Journal:  J Clin Oncol       Date:  2001-07-15       Impact factor: 44.544

7.  2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

Authors:  A du Bois; M Quinn; T Thigpen; J Vermorken; E Avall-Lundqvist; M Bookman; D Bowtell; M Brady; A Casado; A Cervantes; E Eisenhauer; M Friedlaender; K Fujiwara; S Grenman; J P Guastalla; P Harper; T Hogberg; S Kaye; H Kitchener; G Kristensen; R Mannel; W Meier; B Miller; J P Neijt; A Oza; R Ozols; M Parmar; S Pecorelli; J Pfisterer; A Poveda; D Provencher; E Pujade-Lauraine; M Randall; J Rochon; G Rustin; S Sagae; F Stehman; G Stuart; E Trimble; P Vasey; I Vergote; R Verheijen; U Wagner
Journal:  Ann Oncol       Date:  2005       Impact factor: 32.976

8.  Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.

Authors:  John K Chan; Mark F Brady; Richard T Penson; Helen Huang; Michael J Birrer; Joan L Walker; Paul A DiSilvestro; Stephen C Rubin; Lainie P Martin; Susan A Davidson; Warner K Huh; David M O'Malley; Matthew P Boente; Helen Michael; Bradley J Monk
Journal:  N Engl J Med       Date:  2016-02-25       Impact factor: 91.245

9.  Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

Authors:  Paul A Vasey; Gordon C Jayson; Alan Gordon; Hani Gabra; Rob Coleman; Ronnie Atkinson; David Parkin; James Paul; Andrea Hay; Stan B Kaye
Journal:  J Natl Cancer Inst       Date:  2004-11-17       Impact factor: 13.506

10.  BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.

Authors:  J L Lesnock; K M Darcy; C Tian; J A Deloia; M M Thrall; C Zahn; D K Armstrong; M J Birrer; T C Krivak
Journal:  Br J Cancer       Date:  2013-03-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.